Retatrutide

20mg

Retatrutide is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. This multi-receptor approach has been the focus of extensive metabolic research, with studies examining its effects on glucose homeostasis, energy expenditure, and body composition in preclinical and clinical models. The 20mg formulation provides a higher research-grade quantity for extended investigative protocols.